Official Title: A Proof-of-concept, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Assess the Prophylactic Antiviral Activity Against Influenza, Safety, Tolerability, and Pharmacokinetics of CD388 Via a Human Viral Challenge Model
Actual Study Start Date : September 9, 2022
Estimated Primary Completion Date : July 2023
Estimated Study Completion Date : July 2023